Latest Regulatory Approval News

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.

Beacon Minerals has secured key regulatory approvals to launch multiple drilling programs at its Lady Ida Iguana Project, setting the stage for intensified exploration activity over the coming months.

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.

Osteopore Limited has announced a $20 million convertible notes offering aimed at bolstering its capital for ongoing operations and future projects. The highly speculative offer targets sophisticated investors and underscores the company’s strategic funding approach amid competitive medical device markets.

Arika Resources has identified extensive gold-bearing quartz reefs stretching over 4.5 kilometres at Banjo's Camp within the Yundamindra Gold Project, with rock chip samples grading up to 5.3 g/t Au. This discovery significantly expands the project's exploration potential ahead of planned drilling campaigns.

Evolution Mining has reported a landmark first half of FY25 with a 277% jump in statutory net profit and a substantial 250% increase in its interim dividend, underscoring robust operational momentum and shareholder returns.

Evolution Mining Limited has reported a record statutory net profit after tax of $365.1 million for the half-year ended December 31, 2024, driven by strong operational performance and higher gold and copper prices. The company also declared a fully franked interim dividend of 7.0 cents per share, continuing its consistent shareholder returns.

St Barbara Limited has announced its intention to separate its Atlantic Gold Operations in Nova Scotia, aiming to unlock value through a Canadian-led development while concentrating on its Papua New Guinea assets.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Suncorp Group Limited has announced a cash return of capital of AUD 3.00 per share, backed by shareholder and regulatory approvals, with payments scheduled for early March 2025.

Suncorp Group Limited has announced a combined ordinary and special dividend totaling AUD 0.63 per security, fully franked and backed by APRA approval for a capital reduction. The payment is scheduled for mid-March 2025.